Evotec AG has agreed a collaboration with Apeiron Biologics AG to identify small molecule modulators of the Downstream Regulatory Element Antagonistic Modulator or DREAM, a novel target implicated in pain.
Evotec will now apply its expertise in cellular assay development to move the project into hit identification.
Hans Loibner, Chief Executive Officer at Apeiron Biologics, said, “Combining our two companies’ skills is an excellent way to move forward with this innovative and promising project. We have worked with...
This page requires a Science|Business Network Membership
This page is available to Science|Business Network Members only. If you are already a member then please log in (above).
Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.
Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.
Be where innovation begins – become a member. Click here to learn more.